Introduction of Polymerase Chain Reaction (PCR) in Microbiology and Parasitology
NCT ID: NCT07269314
Last Updated: 2025-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2023-09-01
2026-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Furthermore, we would evaluate these methods in terms of cost effectiveness towards classical direct methods, which are now operator-dependent.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers
NCT06307171
Miltefosine for Mucosal Leishmaniasis
NCT00373776
LAMP Assay for the Diagnosis of Visceral Leishmaniasis
NCT04003532
Clinical Investigation of Infections Due to Leishmanial Parasites
NCT00001169
Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis with Inhaled Pentamidine Plus Oral Miltefosine
NCT06550609
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Positive samples for Leishmania amastygotes in peripheral blood and/or bone marrow aspirate/biopsy and/or from cutaneous scraping/biopsy previously tested according to routine diagnostic assays will be tested with a specific qualitative PCR analysis by using commercial diagnosis kit. In addition, we would perform a system of DNA quantification using PCR cycle threshold of the single sample and a virtual scale able to convert the results in the DNA load (Piralla A et al, J clin virol 2013). Then we would perform a specific DNA sequencing of p70 gene to determine specie and the strain.
2. Plasmodium species blood positive samples tested for and analyzed by direct microscopy and immunocromatographic assay, will be tested with multiplex PCR commercial diagnostic kit or with a described method (A.Berg et al, Infection 2020) able to determine single or mixed infection and to quantify the parasitemia respectively. In detail, the blood samples will be analyzed with qualitative and quantitative PCR analysis for Plasmodium spp and Plasmodium Falciparum, respectively. The concentration of P. falciparum DNA in blood samples will be measured by quantitative real-time PCR (qPCR) as described elsewhere (Imwong M, J.clin.microb 2014). In Plasmodium falciparum positive samples, the amount of DNA copies obtained from each sample will be compared with the level of parasitemia obtained from direct microscopy analysis. In this way we would like to determine a range of DNA copy values comparable to the different degrees of classification that are currently obtained with percentages of red blood cells positive for the infection (\<5% vs \>5%). In this way, it could be possible to assess a level of parasitemia with quantitative PCR techniques.
3. Finally, detection of Pneumocistis jirovecii in positive BAL or bronchoaspirate (BAS) samples obtained by direct microscopy will be reanalyzed by using PCR commercial diagnostic kit. As previously mentioned, the CT value will be converted in DNA load in comparison with direct microscopy data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione IRCCS Policlinico San Matteo di Pavia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stefania Paolucci
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P_41
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.